A Metabolic Key to Polycystic Kidney Disease
A new study in Experimental & Molecular Medicine reveals a critical link between immune-related metabolic reprogramming and autosomal recessive polycystic kidney disease (ARPKD). Researchers identified that the transcription factor GLIS3, when dysfunctional, triggers a shift toward aerobic glycolysis in kidney cells, a process reminiscent of the Warburg effect often seen in immune cell activation and cancer. This metabolic shift is driven by the upregulation and altered function of the enzyme PKM2. Using a mouse model, the team demonstrated that pharmacological inhibition of PKM2 significantly reduced cyst growth and number, highlighting a potential therapeutic pathway for this serious genetic condition leading to renal failure.
Study Significance: This research bridges immunometabolism and organ-specific pathology, showing how pathways central to immune cell function, like aerobic glycolysis, can drive disease in non-immune tissues. For immunologists, it underscores the broader relevance of metabolic checkpoints like PKM2 beyond classic immunology, offering a novel angle for therapeutic intervention in genetic disorders. The findings suggest that targeting metabolic reprogramming, a strategy explored in oncology and immunotherapy, could be repurposed for treating cystic kidney diseases.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
